FOLD (Amicus Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

FOLD (Amicus Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

Mkt Cap$5B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$634M

Net Income (TTM)-$27M

EPS (TTM)-$0.09

Free Cash Flow (TTM)$30M

Gross Margin87.9%

Op. Margin5.2%

Net Margin-4.3%

FCF Margin4.7%

P/S Ratio (TTM)7.1x

P/E Ratio (TTM)—

YoY Rev Growth+20.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$86M	$79M	-$38M
Q2 23	$95M	$85M	-$19M
Q3 23	$104M	$94M	-$17M
Q4 23	$115M	$104M	-$4M
Q1 24	$110M	$97M	-$28M
Q2 24	$127M	$115M	$15M
Q3 24	$142M	$128M	$22M
Q4 24	$150M	$135M	$16M
Q1 25	$125M	$114M	-$8M
Q2 25	$155M	$139M	-$9M
Q3 25	$169M	$148M	$34M
Q4 25	$185M	$157M	$16M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	13.4x	—
Q2 23	12.9x	—
Q3 23	12.1x	—
Q4 23	11.3x	—
Q1 24	10.6x	—
Q2 24	9.9x	—
Q3 24	9.1x	—
Q4 24	8.5x	—
Q1 25	8.3x	—
Q2 25	7.9x	—
Q3 25	7.5x	—
Q4 25	7.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$18M	-$20M
Q2 23	-$16M	-$18M
Q3 23	-$38M	-$40M
Q4 23	$3M	$2M
Q1 24	-$30M	-$32M
Q2 24	$23M	$22M
Q3 24	-$23M	-$23M
Q4 24	-$4M	-$4M
Q1 25	$8M	$8M
Q2 25	-$27M	-$29M
Q3 25	$36M	$35M
Q4 25	$16M	$16M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2M
Q2 23	$2M
Q3 23	$2M
Q4 23	$2M
Q1 24	$2M
Q2 24	$1M
Q3 24	$356K
Q4 24	$288K
Q1 25	$212K
Q2 25	$2M
Q3 25	$382K
Q4 25	$299K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+9.6%	-19.6%
Q2 23	+17.1%	-19.8%
Q3 23	+26.7%	+4.3%
Q4 23	+30.6%	-8.9%
Q1 24	+28.0%	+11.5%
Q2 24	+34.0%	-1.5%
Q3 24	+36.7%	-0.6%
Q4 24	+30.1%	+12.6%
Q1 25	+13.4%	-3.6%
Q2 25	+22.1%	+47.0%
Q3 25	+19.5%	+12.5%
Q4 25	+23.7%	+26.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$35M	40.4%
Q2 23	$17M	17.5%
Q3 23	$17M	16.0%
Q4 23	$0	0.0%
Q1 24	$31M	27.9%
Q2 24	$16M	12.8%
Q3 24	$19M	13.2%
Q4 24	$19M	12.8%
Q1 25	$25M	20.1%
Q2 25	$18M	11.4%
Q3 25	$18M	10.7%
Q4 25	$27M	14.4%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$41M	$74M
Q2 23	$35M	$65M
Q3 23	$41M	$66M
Q4 23	$35M	$70M
Q1 24	$28M	$88M
Q2 24	$25M	$74M
Q3 24	$26M	$75M
Q4 24	$30M	$87M
Q1 25	$28M	$92M
Q2 25	$61M	$85M
Q3 25	$23M	$90M
Q4 25	$24M	$117M

Revenue by Geography

Quarter	Non-US	United States
Q1 23	$57M	$29M
Q2 23	$57M	$37M
Q3 23	$66M	$38M
Q4 23	$72M	$43M
Q1 24	$73M	$37M
Q2 24	$77M	$50M
Q3 24	$85M	$56M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$161M	$107M	$267M
Q2 23	$211M	$54M	$266M
Q3 23	$263M	$17M	$280M
Q4 23	$247M	$39M	$286M
Q1 24	$210M	$30M	$240M
Q2 24	$209M	$51M	$260M
Q3 24	$234M	$16M	$250M
Q4 24	$214M	$36M	$250M
Q1 25	$182M	$69M	$251M
Q2 25	$159M	$72M	$231M
Q3 25	$191M	$73M	$264M
Q4 25	$214M	$80M	$294M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	291M	+3.6%
Q2 23	293M	+0.5%
Q3 23	296M	+1.0%
Q4 23	294M	-0.7%
Q1 24	303M	+3.2%
Q2 24	304M	+0.3%
Q3 24	305M	+0.3%
Q4 24	299M	-1.9%
Q1 25	308M	+2.9%
Q2 25	308M	+0.2%
Q3 25	310M	+0.7%
Q4 25	314M	+1.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$13K	97
FY 15	$0	185
FY 16	$19K	263
FY 17	$114K	325
FY 18	$180K	508
FY 19	$312K	584
FY 20	$540K	483
FY 21	$616K	496
FY 22	$680K	484
FY 23	$772K	517
FY 24	$1M	499
FY 25	$16K	40K